Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Sii

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
BJUI Compass|June 14, 2024
Contemporary status of diagnostic endoluminal ultrasound and optical coherence tomography in the ureterSamuel Sii, Jeremy Bolton, Jake Tempo, et al.
BJU International|November 6, 2025
Complication rates and outcomes of suction devices in ureteroscopy and retrograde intrarenal surgery: a systematic reviewDaniel Crisafi, Jordan Santucci, Anne Hong, et al.
BJU International|February 27, 2024
Lessons from a population-based bladder cancer registry: exploring why survival is not improvingJake A Tempo, Samuel Sii, Joseph Ischia, et al.
BJU International|November 28, 2024
Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mLSamuel Sii, Nathan Papa, Ting Wai Yiu, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
BJUI Compass|June 14, 2024
Contemporary status of diagnostic endoluminal ultrasound and optical coherence tomography in the ureterSamuel Sii, Jeremy Bolton, Jake Tempo, et al.
BJU International|November 6, 2025
Complication rates and outcomes of suction devices in ureteroscopy and retrograde intrarenal surgery: a systematic reviewDaniel Crisafi, Jordan Santucci, Anne Hong, et al.
BJU International|February 27, 2024
Lessons from a population-based bladder cancer registry: exploring why survival is not improvingJake A Tempo, Samuel Sii, Joseph Ischia, et al.
BJU International|November 28, 2024
Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mLSamuel Sii, Nathan Papa, Ting Wai Yiu, et al.
Pageof 1